AlphAIAlphAI — Financial news for AI agents
theglobeandmail.comSEP 52 min read$ABBV

Scotiabank Remains a Buy on AbbVie (ABBV)

Scotiabank's Louise Chen maintained a Buy rating on AbbVie (ABBV) with a $280 price target. AbbVie reported Q2 revenue of $16.99B and net profit of $3.61B. Insider sentiment is negative, with recent sales by executives.

Original reporting
theglobeandmail.com
Published Sep 5, 2026, 11:51 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 5, 2026, 10:41 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Scotiabank Remains a Buy on AbbVie (ABBV) — source image
Source · theglobeandmail.com
Decision brief

The 30-second read

$ABBVBullishMed
01

Why it matters

Earnings beat and analyst upgrades suggest short‑term upside, but insider selling adds caution.

02

Market read

AbbVie's earnings and upgraded targets could drive modest buying in the stock and sector.

03

What to watch

Potential headwinds from generic competition and pipeline risks.

Relevance 8/10Novelty 8/10Timing: today

Background

AbbVie reported Q2 revenue of $16.99B and net profit of $3.61B, up from prior year.

Company-level read

Ticker impact

$ABBVBullishHigh confidence
Context

Scotiabank and Piper Sandler reaffirm Buy ratings with a $280 price target after AbbVie's Q2 earnings release.

Expected impact

Potential modest price appreciation if market absorbs the higher target.

Evidence & confidence

Buy rating and $280 target reflect confidence in earnings beat and growth outlook.

Market effects

Sector

Positive sentiment may lift other large‑cap pharma stocks.

Regional

U.S. healthcare sector may see modest gains.

Global

Limited to U.S. and global pharma investors.

Counterpoint

What could challenge this read

Target may be overly optimistic given competitive pressures.

Key entities

  • analyst
    Scotiabank

    Maintained Buy rating with $280 target.

  • analyst
    Piper Sandler

    Also issued a Buy rating.

  • analyst
    Citi

    Maintained Hold rating.

Read at source← All news

Related articles

OCT 22
$ABBVMedAI 8/10

Great News for AbbVie Stock Investors

AbbVie (NYSE:ABBV) shares have risen 26% this year due to strong financial performance. The company's growth is driven by Skyrizi and Rinvoq, with Skyrizi generating $10B in H1 sales. AbbVie is developing ABBV-466, a potential successor to Skyrizi, and acquired Apogee Therapeutics for $10.9B to bolster its immunology portfolio. The company also has a strong pipeline and a 2.5% dividend yield.

finance.yahoo.com3 min
OCT 22
$ABBVMed

AbbVie’s skin disease drug lessens abscess burden in Phase 3 but falls below expectations

AbbVie's Phase 3 trial for lutikizumab in hidradenitis suppurativa met its primary endpoint but fell short of analyst expectations. The drug showed an 8% placebo-adjusted response rate, below mid-phase data. Analysts have mixed views on its commercial potential. AbbVie plans further studies and combinations with other drugs. Avalo Therapeutics' shares dropped due to perceived overlap with lutikizumab.

biospace.com2 min
OCT 22
$ABBVMedAI 8/10

AbbVie's Lutikizumab Hits Phase 3 Goal

AbbVie (ABBV) reported positive phase 3 results for lutikizumab in treating hidradenitis suppurativa, with 31.4% of patients achieving HiSCR75 at week 16. The treatment also met secondary goals, including pain reduction and fewer flares. More data and regulatory filings are expected in 2027.

gurufocus.com2 min
OCT 22
$MLTXHighAI 8/10

MoonLake Soars 18% as Rival AbbVie’s Skin Disease Trial Data “Underwhelms”

MoonLake Immunotherapeutics (MLTX) shares rose 18% after AbbVie (ABBV) reported Phase 3 trial results for a competing hidradenitis suppurativa drug. AbbVie's lutikizumab showed an 8-point improvement over placebo, which RBC Capital deemed underwhelming. MoonLake's sonelokimab previously demonstrated a 14-point improvement in a similar trial. MoonLake awaits FDA review of its drug application, submitted on Sept. 30, with a potential US launch in late 2027.

finance.yahoo.com2 min